Abstract
Angiotensin Receptor Blockers for the Prevention of Atrial Fibrillation Recurrences: Unending Hot Debate
Highlights
How angiotensin inhibition might protect against AF is not completely known
In contrast to the earlier data, GISSI-AF found that valsartan did not prevent recurrent AF
At 1 year follow-up, there was no significant difference between valsartan or placebo in the proportion of patients who had more than 1 episode of AF or in the median time from randomization to the first recurrence of AF
Summary
How angiotensin inhibition might protect against AF is not completely known. There is a plausible scientific basis for the notion that inhibition of the renin-angiotensin system can reduce the incidence of AF.[1]. In contrast to the earlier data, GISSI-AF found that valsartan did not prevent recurrent AF.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
